Frontiers in Molecular Medicine and Therapeutics最新文献

Melatonin in molecular medicine and therapy: A frontier ally in health and disease 褪黑素在分子医学和治疗中的应用:健康和疾病的前沿

Frontiers in Molecular Medicine and Therapeutics Pub Date : 2022-02-27 DOI: 10.36879/fmmt.22.000105

Mateos Ag

引用次数: 0

Hepatocellular carcinoma: Causes, putative biomarkers, and current therapies 肝细胞癌:病因、推测的生物标志物和目前的治疗方法

Frontiers in Molecular Medicine and Therapeutics Pub Date : 2021-10-24 DOI: 10.36879/fmmt.21.000104

{"title":"Hepatocellular carcinoma: Causes, putative biomarkers, and current therapies","authors":"","doi":"10.36879/fmmt.21.000104","DOIUrl":"https://doi.org/10.36879/fmmt.21.000104","url":null,"abstract":"Recent advances in molecular diagnostic technologies continue to facilitate the discovery of diverse cellular signaling pathways that\u0000are involved in the development and progression of hepatocellular carcinoma (HCC). HCC accounted for 30,000 cancer-related\u0000deaths in the United States (U.S.) in 2020. In the era of personalized medicine that has led to improved therapies for many cancers,\u0000the efficacy of current anti-HCC therapies remains modest at best. Although significant advances in basic science research have\u0000identified alterations of cellular, genetic, and epigenetic signals that influence HCC development, and some of these have led to the\u0000development of anti-HCC therapies, overall, HCC cures continue to be elusive. Moreover, tumor-related changes in the microbiome\u0000and the tumor microenvironment have been identified and have revealed multiple potential pathways that can either aid in diagnosing\u0000HCC or serve as new therapeutic targets. However, even here, there is a need to translate these observations into a clinical outcome,\u0000and HCC typically has a poor prognosis.\u0000 In any clinical scenario, the clinical oncologist starts by identifying risk factors, followed by using diagnostic tools, including testing\u0000for specific biomarkers, to help diagnose the stage of the disease, which aids in selecting the best treatment options to improve the\u0000patient’s prognosis. In this review, we will follow a similar pathway by first providing a description of HCC risk factors, biomarkers,\u0000and diagnostic tools and then discussing treatment options. Rather than provide a historical review, we will focus on the most current\u0000HCC biomarkers and treatments that have been published and will integrate the results of recent basic science research on cellular\u0000signals that are altered in HCC, especially where these have contributed to novel HCC therapies.","PeriodicalId":415386,"journal":{"name":"Frontiers in Molecular Medicine and Therapeutics","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128799020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tea flavonoids inhibiting multiple proteins related to SARS-CoV-2 judged from molecular docking 从分子对接判断茶黄酮抑制SARS-CoV-2相关多种蛋白

Frontiers in Molecular Medicine and Therapeutics Pub Date : 2021-09-17 DOI: 10.36879/fmmt.21.000102

{"title":"Tea flavonoids inhibiting multiple proteins related to SARS-CoV-2 judged from molecular docking","authors":"","doi":"10.36879/fmmt.21.000102","DOIUrl":"https://doi.org/10.36879/fmmt.21.000102","url":null,"abstract":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused Coronavirus Disease 2019 (COVID-19) pandemic.\u0000Flavonoids-derived Chinese patent medicines have outstanding curative effects for the improvement and treatment of COVID-19.\u0000Numerous studies were suggesting that flavonoid-rich tea has antiviral effects. In vitro studies demonstrated that bioactive compounds\u0000of tea flavonoids could inhibit the activity of SARS-CoV-2 main protease (Mpro). However, bioactive compounds from tea flavonoids\u0000with antiviral effect, and the potential molecular mechanisms are unclear. In this study, we performed a molecular docking of 468\u0000tea flavonoids and their derivatives with Mpro, RNA-dependent RNA polymerase (RdRp), angiotensin-converting enzyme 2 (ACE2),\u0000compared with the positive clinical drugs of each target. The results suggest that ACE2 and RdRp are the main targets inhibited by tea\u0000flavonoids according to the binding affinity. Quercetin 3-glycosides (Q3G), Isovitexin, and 4’,5,7-Trihydroxyflavanone 7-O-Fructoside\u0000(S)-form (TF) would be considered as the potential candidate compounds of RdRp and ACE2. Our study provides a theoretical basis\u0000for further drug design of anti-COVID-19 bioactive compounds.","PeriodicalId":415386,"journal":{"name":"Frontiers in Molecular Medicine and Therapeutics","volume":"73 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134340824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A new method for determining drug half-life and evaluating stability 一种测定药物半衰期和评价药物稳定性的新方法

Frontiers in Molecular Medicine and Therapeutics Pub Date : 2021-09-05 DOI: 10.36879/fmmt.21.000101

引用次数: 0